Comparative treatment effectiveness of oral fingolimod and injectable disease modifying agents in multiple sclerosis

被引：0
|
作者：
Earla, Jagadeswara Rao [1 ]
Hutton, George Joseph [2 ]
Thornton, J. Douglas [1 ]
Chen, Hua [1 ]
Johnson, Michael L. [1 ]
Aparasu, Rajender R. [1 ]
机构：
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3956
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [21] Treatment effectiveness of oral disease-modifying agent in multiple sclerosis adjusting for adherence trajectories
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Aparasu, Rajender R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 18 - 19
  • [22] Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis
    Iaffaldano, P.
    Viterbo, R. G.
    Lucisano, G.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 687 - 687
  • [23] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Carole Dembek
    Leigh Ann White
    Jayson Quach
    Andrea Szkurhan
    Nazia Rashid
    M. R. Blasco
    The European Journal of Health Economics, 2014, 15 : 353 - 362
  • [24] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Dembek, Carole
    White, Leigh Ann
    Quach, Jayson
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04): : 353 - 362
  • [25] Critical Appraisal of Effectiveness of Oral Fingolimod in Relapsing Multiple Sclerosis
    Pinzon, Rizaldy
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 334 - 335
  • [26] THE COST EFFECTIVENESS OF FINGOLIMOD FOR THE TREATMENT MULTIPLE SCLEROSIS IN KOREA
    Lee, J.
    Ko, S.
    VALUE IN HEALTH, 2017, 20 (09) : A724 - A724
  • [27] Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Vartanian, TK
    Zamvil, SS
    Fox, E
    Sorensen, PS
    NEUROLOGY, 2004, 63 (11) : S42 - S49
  • [28] Disease-modifying agents in multiple sclerosis
    Coyle, P. K.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2009, 12 (04) : 273 - 282
  • [29] Comparative effectiveness of natalizumab and fingolimod treatment on cognitive outcomes in relapsing multiple sclerosis patients
    Iaffaldano, P.
    Viterbo, R. G.
    Lucisano, G.
    Paolicelli, D.
    Pippolo, L.
    Baroncini, D.
    Zaffaroni, M.
    Ghezzi, A.
    Trojano, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 418 - 419
  • [30] TREATMENT PATTERNS AND PERSISTENCE TO ORAL AND INJECTABLE MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES BETWEEN THE UNITED STATES AND EUROPE
    Galaznik, A.
    Ransom, J.
    Shilnikova, A.
    Rusli, E.
    Lempernesse, B.
    Berger, M.
    VALUE IN HEALTH, 2020, 23 : S277 - S277
12345